Archives of General Internal Medicine

Reach Us +1 (202) 780-3397

Rapid Communication - Archives of General Internal Medicine (2024) Volume 8, Issue 3

The role of immunotherapy in cancer treatment: Current trends and future prospects

Paul Becker *

Department of Internal Medicine, University of Lorraine, France

*Corresponding Author:
Paul Becker
Department of Internal Medicine, University of Lorraine, France
E-mail: p.becker576@chru-nancy.fr

Received: 27-May-2024, Manuscript No. AAAGIM-24-136822; Editor assigned: 30-May-2024, PreQC No. AAAGIM-24-136822 (PQ); Reviewed: 13-Jun-2024, QC No. AAAGIM-24-136822; Revised: 17-Jun-2024, Manuscript No. AAAGIM-24-136822(R); Published: 24-Jun-2024, DOI:10.35841/aaagim-8.3.232

Citation: : Becker P. The role of immunotherapy in cancer treatment: Current trends and future prospects. Arch Gen Intern Med. 2024;8(3):232.

Visit for more related articles at Archives of General Internal Medicine

Introduction

Immunotherapy, harnessing the body's own immune system to target and destroy cancer cells, has transformed the landscape of cancer treatment. From melanoma to lung cancer to leukemia, immunotherapy has shown remarkable efficacy across a spectrum of malignancies, offering new hope to patients who once faced dire prognoses. In this article, we explore the current trends and future prospects of immunotherapy in cancer treatment. At the core of immunotherapy lies the principle of leveraging the immune system's innate ability to recognize and eliminate foreign invaders, including cancer cells. Unlike traditional treatments that directly target cancer cells, immunotherapy works by enhancing the body's immune response or by removing the barriers that cancer cells use to evade detection and destruction [1, 2].

Another form of immunotherapy involves adoptive cell transfer, where immune cells, such as T cells, are isolated from the patient, genetically modified or enhanced in the laboratory, and then infused back into the patient to target and destroy cancer cells. Chimeric Antigen Receptor (CAR) T-cell therapy is a notable example of adoptive cell transfer, showing remarkable success in certain blood cancers. Additionally, immune system modulators, such as cytokines and immune checkpoint agonists, are being investigated to stimulate the immune response against cancer. These approaches aim to fine-tune the immune system's activity, either by boosting its cytotoxic capabilities or by overcoming the immunosuppressive mechanisms employed by cancer cells [3, 4].

Combinatorial approaches that leverage the synergistic effects of different immunotherapeutic agents or combine immunotherapy with other treatment modalities, such as chemotherapy or targeted therapy, are increasingly being investigated. These combinations aim to enhance efficacy, overcome resistance, and reduce the likelihood of tumor recurrence. The identification of predictive biomarkers, such as PD-L1 expression or tumor mutational burden, has become integral to patient selection and treatment optimization in immunotherapy. Biomarker-driven approaches help identify patients who are most likely to benefit from immunotherapy and guide treatment decisions in clinical practice [5, 6].

Ongoing research efforts are focused on developing novel immunotherapeutic approaches, including novel checkpoint inhibitors, engineered immune cells, oncolytic viruses, and cancer vaccines. These next-generation therapies aim to further enhance the potency and specificity of immune-mediated antitumor responses. Resistance to immunotherapy remains a significant challenge, with many patients experiencing either primary or acquired resistance to treatment. Understanding the mechanisms underlying resistance and developing strategies to overcome it, such as combination therapies and immune modulators, is a critical area of investigation [7, 8].

The tumor microenvironment plays a pivotal role in immune evasion, creating an immunosuppressive milieu that hampers effective antitumor immunity. Therapeutic strategies aimed at reprogramming the tumor microenvironment to promote immune activation and infiltration hold promise for enhancing the efficacy of immunotherapy. Despite its clinical success, immunotherapy remains inaccessible to many patients due to factors such as high costs, limited availability, and disparities in healthcare access. Efforts to expand access to immunotherapy, improve affordability, and address disparities in care are essential for ensuring equitable access to these life-saving treatments [9, 10].

Conclusion

Immunotherapy has emerged as a transformative approach in the field of cancer treatment, offering new hope and improved outcomes for patients with various malignancies. With on-going research and innovation, the future of immunotherapy holds great promise for further advancing the frontiers of cancer care and ultimately improving the lives of patients worldwide.

References

  1. Wei C, Lan X, Qiu M, et al. Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer. Oncol Lett. 2023;26(3):1-6.

    2. Indexed at, Google Scholar, Cross Ref

  2. Zeng Z, Yang B, Liao Z, et al. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer. Future Oncol. 2021;17(12):1553-69.

    3. Indexed at, Google Scholar, Cross Ref

  3. Mody MD, Gill HS, Saba NF, et al. The evolving and future role of taxanes in squamous cell carcinomas of the head and neck: a review. JAMA Otolaryngol Head Neck Surg. 2016; 142(9):898-905.

    4. Indexed at, Google Scholar, Cross Ref

  4. Kalos M. Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine. 2003;21(7-8):781-6.

    5. Indexed at, Google Scholar, Cross Ref

  5. Takahashi H, Nishibori M. Current status and future prospects in HMGB1 and receptor researches. Nihon Rinsho. Japanese journal of clinical medicine. 2016;74(4):703-11.

    6. Indexed at, Google Scholar

  6. Madan RA, Gulley JL. Prospects for the future of prostate cancer vaccines. Expert Rev Vaccines. 2016;15(3):271-4.

    7. Indexed at, Google Scholar, Cross Ref

  7. Dalakas M. IVIg in other autoimmune neurological disorders: current status and future prospects. J Neurol. 2008;255:12-6.

    8. Indexed at, Google Scholar, Cross Ref

  8. Wang Y, Ren S, Wang Z, et al. Chemokines in bone-metastatic breast cancer: Therapeutic opportunities. Int Immunopharmacol. 2020;87:106815.

    9. Indexed at, Google Scholar, Cross Ref

  9. Pulsipher MA, Woolfrey A. NONMYELOABLATIVE TRANSPLATATION IN CHILDREN:  Status and Future Prospects. Hematol Oncol Clin North Am. 2001;15(5):809-34.

    10. Indexed at, Google Scholar, Cross Ref

  10. Srivastava SC. Is there life after technetium: what is the potential for developing new broad-based radionuclides?. Semin Nucl Med. 1996; 26(2):119-131.

    11. Indexed at, Google Scholar, Cross Ref

Get the App